000135950 001__ 135950
000135950 005__ 20240229105047.0
000135950 0247_ $$2doi$$a10.1002/ijc.31283
000135950 0247_ $$2pmid$$apmid:29377173
000135950 0247_ $$2ISSN$$a0020-7136
000135950 0247_ $$2ISSN$$a1097-0215
000135950 0247_ $$2altmetric$$aaltmetric:32416257
000135950 037__ $$aDKFZ-2018-00687
000135950 041__ $$aeng
000135950 082__ $$a610
000135950 1001_ $$0P:(DE-He78)31d7c3e829be03400641f80b821ef728$$aButt, Julia Anna$$b0$$eFirst author
000135950 245__ $$aProspective evaluation of antibody response to Streptococcus gallolyticus and risk of colorectal cancer.
000135950 260__ $$aBognor Regis$$bWiley-Liss$$c2018
000135950 3367_ $$2DRIVER$$aarticle
000135950 3367_ $$2DataCite$$aOutput Types/Journal article
000135950 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1680772054_21950
000135950 3367_ $$2BibTeX$$aARTICLE
000135950 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000135950 3367_ $$00$$2EndNote$$aJournal Article
000135950 520__ $$aThe gut microbiome is increasingly implicated in colorectal cancer (CRC) development. A subgroup of patients diagnosed with CRC show high antibody responses to Streptococcus gallolyticus subspecies gallolyticus (SGG). However, it is unclear whether the association is also present pre-diagnostically. We assessed the association of antibody responses to SGG proteins in pre-diagnostic serum samples with CRC risk in a case-control study nested within a prospective cohort. Pre-diagnostic serum samples from 485 first incident CRC cases (mean time between blood draw and diagnosis 3.4 years) and 485 matched controls in the European Prospective Investigation into Nutrition and Cancer (EPIC) study were analyzed for antibody responses to 11 SGG proteins using multiplex serology. Odds ratios (OR) and 95% confidence intervals (CI) were estimated using multivariable conditional logistic regression models. Antibody positivity for any of the 11 SGG proteins was significantly associated with CRC risk with 56% positive controls compared to 63% positive cases (OR: 1.36, 95% CI: 1.04-1.77). Positivity for two or more proteins of a previously identified SGG 6-marker panel with greater CRC-specificity was also observed among 9% of controls compared to 17% of CRC cases, corresponding to a significantly increased CRC risk (OR: 2.17, 95% CI: 1.44-3.27). In this prospective nested case-control study, we observed a positive association between antibody responses to SGG and CRC development in serum samples taken before evident disease onset. Further work is required to establish the possibly etiological significance of these observations and whether SGG serology may be applicable for CRC risk stratification.
000135950 536__ $$0G:(DE-HGF)POF3-316$$a316 - Infections and cancer (POF3-316)$$cPOF3-316$$fPOF III$$x0
000135950 588__ $$aDataset connected to CrossRef, PubMed,
000135950 7001_ $$aJenab, Mazda$$b1
000135950 7001_ $$0P:(DE-He78)42f09617805f4c475ccb9a3b943ce28a$$aWillhauck-Fleckenstein, Martina$$b2
000135950 7001_ $$0P:(DE-He78)8c4d3a946a1fcde2ded7e17651fd0ed7$$aMichel, Angelika$$b3
000135950 7001_ $$0P:(DE-He78)d99bad949ba3ae93859eedae5ac266da$$aPawlita, Michael$$b4
000135950 7001_ $$00000-0002-9083-8960$$aKyrø, Cecilie$$b5
000135950 7001_ $$aTjønneland, Anne$$b6
000135950 7001_ $$aBoutron-Ruault, Marie-Christine$$b7
000135950 7001_ $$aCarbonnel, Franck$$b8
000135950 7001_ $$aSeveri, Gianluca$$b9
000135950 7001_ $$0P:(DE-He78)4b2dc91c9d1ac33a1c0e0777d0c1697a$$aKaaks, Rudolf$$b10
000135950 7001_ $$0P:(DE-He78)0907a10ba1dc8f53f04907f54f6fdcfe$$aKühn, Tilman$$b11
000135950 7001_ $$aBoeing, Heiner$$b12
000135950 7001_ $$aTrichopoulou, Antonia$$b13
000135950 7001_ $$00000-0003-1441-897X$$ala Vecchia, Carlo$$b14
000135950 7001_ $$aKarakatsani, Anna$$b15
000135950 7001_ $$aPanico, Salvatore$$b16
000135950 7001_ $$aTumino, Rosario$$b17
000135950 7001_ $$aAgnoli, Claudia$$b18
000135950 7001_ $$00000-0002-5558-2437$$aPalli, Domenico$$b19
000135950 7001_ $$00000-0002-8008-5096$$aSacerdote, Carlotta$$b20
000135950 7001_ $$aBueno-de-Mesquita, H B As$$b21
000135950 7001_ $$aWeiderpass, Elisabete$$b22
000135950 7001_ $$aSánchez, Maria-José$$b23
000135950 7001_ $$aBonet Bonet, Catalina$$b24
000135950 7001_ $$aHuerta, José María$$b25
000135950 7001_ $$aArdanaz, Eva$$b26
000135950 7001_ $$00000-0003-3345-7333$$aBradbury, Kathryn$$b27
000135950 7001_ $$aGunter, Marc$$b28
000135950 7001_ $$00000-0003-3347-8249$$aMurphy, Neil$$b29
000135950 7001_ $$aFreisling, Heinz$$b30
000135950 7001_ $$aRiboli, Elio$$b31
000135950 7001_ $$aTsilidis, Kostas$$b32
000135950 7001_ $$aAune, Dagfinn$$b33
000135950 7001_ $$0P:(DE-He78)6b4ebb9791b983b5620c0caaf3468e30$$aWaterboer, Tim$$b34$$eLast author
000135950 7001_ $$aHughes, David J$$b35
000135950 773__ $$0PERI:(DE-600)1474822-8$$a10.1002/ijc.31283$$gVol. 143, no. 2, p. 245 - 252$$n2$$p245 - 252$$tInternational journal of cancer$$v143$$x0020-7136$$y2018
000135950 909CO $$ooai:inrepo02.dkfz.de:135950$$pVDB
000135950 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)31d7c3e829be03400641f80b821ef728$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000135950 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)42f09617805f4c475ccb9a3b943ce28a$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000135950 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)8c4d3a946a1fcde2ded7e17651fd0ed7$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000135950 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)d99bad949ba3ae93859eedae5ac266da$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000135950 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)4b2dc91c9d1ac33a1c0e0777d0c1697a$$aDeutsches Krebsforschungszentrum$$b10$$kDKFZ
000135950 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)0907a10ba1dc8f53f04907f54f6fdcfe$$aDeutsches Krebsforschungszentrum$$b11$$kDKFZ
000135950 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)6b4ebb9791b983b5620c0caaf3468e30$$aDeutsches Krebsforschungszentrum$$b34$$kDKFZ
000135950 9131_ $$0G:(DE-HGF)POF3-316$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vInfections and cancer$$x0
000135950 9141_ $$y2018
000135950 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz
000135950 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000135950 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000135950 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000135950 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bINT J CANCER : 2015
000135950 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000135950 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000135950 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000135950 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000135950 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000135950 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000135950 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bINT J CANCER : 2015
000135950 9201_ $$0I:(DE-He78)F022-20160331$$kF022$$lInfektionen und Krebs-Epidemiologie$$x0
000135950 9201_ $$0I:(DE-He78)F020-20160331$$kF020$$lInfektionen und Krebs-Epidemiologie$$x1
000135950 9201_ $$0I:(DE-He78)C020-20160331$$kC020$$lC020 Epidemiologie von Krebs$$x2
000135950 980__ $$ajournal
000135950 980__ $$aVDB
000135950 980__ $$aI:(DE-He78)F022-20160331
000135950 980__ $$aI:(DE-He78)F020-20160331
000135950 980__ $$aI:(DE-He78)C020-20160331
000135950 980__ $$aUNRESTRICTED